The pharmaceutical company Darnitsa presented a series of drugs to control pain and inflammation in adults and children. According to the International Association for the Study of Pain (IASP), pain is one of the most common reasons why patients visit a doctor. Dmytro Shymkiv, the chairman of the board of directors of Darnitsa Group, recalled this in his interview.
According to him, in the absence of proper treatment, pain can significantly worsen the quality of life not only of a patient, but also of his/her family, as well as cause negative consequences for society as a whole. The severity of pain in many cases can be exacerbated by concurrent conditions such as depression and anxiety. Pain reduces performance and can lead to social isolation and long-term disability.
Darfen is an effective medication to relieve pain and improve the quality of life of patients. A wide range of the brand and a variety of dosage forms allow to choose an optimal solution for the treatment of patients of different ages and with different indications. Currently, four drugs are presented under the Darfen brand: a local analgesic Darfen Gel and oral forms in the form of a gel, tablets and suspensions - Darfen Long, Darfen Kids and Darfen Kids Forte. The medicines are recommended for the symptomatic treatment of mild to moderate pain in migraines, headaches, back pain, menstrual pain, toothache, rheumatic and muscle pain, sports injuries, pain in mild arthritis, signs of cold and flu, sore throat and fever.
The top manager Dmytro Shymkiv, answering a question about the development strategy of the concern, said that within 6 months of this year the pharmaceutical company Darnitsa brought 12 new brands of drugs for the treatment of diseases of the nervous and cardiovascular systems and pain management to the market. Now the company’s portfolio includes 210 brands of medicines, and by the end of 2021 it is planned to supplement it with 25 new drugs.
The products of Darnitsa are exported to 15 countries of the world. The company was founded in 1930 and since 1998 it has been the leader in Ukraine in terms of the production of drugs in kind. The top manager also recalled that the company’s mission is to help medical workers and patients improve the quality of life through science, innovations and accessibility.